Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO  by Scarabelli, Tiziano M. et al.
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OBJECTIVES This study is aimed at investigating the novel use of minocycline for cardiac protection during
ischemia/reperfusion (I/R) injury, as well as its mechanism of action.
BACKGROUND Minocycline is a tetracycline with anti-inflammatory properties, which is used clinically for
the treatment of diseases such as urethritis and rheumatoid arthritis. Experimentally,
minocycline has also been shown to be neuroprotective in animal models of cerebral ischemia
and to delay progression and improve survival in mouse models of neurodegenerative diseases.
METHODS We studied 62 rat intact hearts exposed to I/R and cell cultures of neonatal and adult rat
ventricular myocytes.
RESULTS Minocycline significantly reduced necrotic and apoptotic cell death, both in neonatal and
adult myocytes, not only when given prior to hypoxia (p  0.001), but also at reoxygenation
(p  0.05). Moreover, in the intact heart exposed to I/R, in vivo treatment with minocycline
promoted hemodynamic recovery (p  0.001) and cell survival, with reduction of infarct size
(p  0.001), cardiac release of creatine phosphokinase (p  0.001), and apoptotic cell death
(p  0.001). In regard to its antiapoptotic mechanism of action, minocycline significantly
reduced the expression level of initiator caspases, increased the ratio of XIAP to Smac/
DIABLO at both the messenger RNA and protein level, and prevented mitochondrial release
of cytochrome c and Smac/DIABLO (all, p  0.05). These synergistic actions dramatically
prevent the post-ischemic induction of caspase activity associated with cardiac I/R injury.
CONCLUSIONS Because of its safety record and multiple novel mechanisms of action, minocycline may be a
valuable cardioprotective agent to ameliorate cardiac dysfunction and cell loss associated with
I/R injury. (J Am Coll Cardiol 2004;43:865–74) © 2004 by the American College of
Cardiology Foundationp
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sinocycline is a semisynthetic second-generation tetracy-
line with proven safety, which is used in humans for the
reatment of acne and urethritis (1). The drug may also be
onsidered for treatment of severe chronic inflammatory
iseases, such as rheumatoid arthritis, as it exerts anti-
nflammatory effects that are completely separate and dis-
inct from its antimicrobial action (2).
It has been shown that minocycline protects the brain in
odent models of global and focal cerebral ischemia (3,4).
ignificant neuroprotection has been attributed to decreased
xpression of caspase-1 and cyclooxygenase 2 (3,4) and to
nhibition of the inducible form of nitric oxide synthase
iNOS) (5). Remarkable neuroprotection has also been
bserved in other experimental models of neurodegenera-
ion. In a transgenic mouse model of Huntington’s disease,
or instance, minocycline delayed disease progression and
From the *Division of Cardiology and †Division of Internal Medicine, St. John
ospital and Medical Center, Detroit, Michigan; ‡Institute of Child Health,
niversity College London, London, England; §Cardiovascular Pathophysiology
esearch Centre, S. Maugeri Foundation, IRCCS Gussago, Italy; Division of
ardiovascular Surgery, Jackson Memorial Hospital, University of Miami, Miami,
lorida; ¶Department of Cystic Fibrosis, National Heart and Lung Institute, Imperial
ollege London, London, England, .
Manuscript received May 19, 2003; revised manuscript received July 25, 2003,pccepted September 8, 2003.rolonged survival both by inhibiting caspase-1 and
aspase-3 messenger RNA up-regulation, and by decreasing
he activity of iNOS (6). Although minocycline-mediated
europrotection has been extensively reported, no corre-
ponding data are yet available about the potentially bene-
cial effects of minocycline as a cardioprotective agent
gainst ischemia/reperfusion (I/R) injury. Therefore, the
resent study was designed to evaluate the cardioprotective
ffectiveness and mechanism of action of minocycline dur-
ng I/R injury both in primary cultures of myocytes and in
he intact heart.
ETHODS
rimary cultures of myocytes. Ventricular myocytes iso-
ated from neonatal Sprague-Dawley rats were cultured as
escribed previously (6). Briefly, after collagenase digestion,
ells were pre-plated in medium consisting of Dulbecco’s
odified Eagle Medium (DMEM), supplemented with
5% (v/v) fetal calf serum (FCS) on 10 cm tissue culture
ishes to allow contaminating fibroblasts to attach and
yocytes remain free within the culture media. Myocyte cell
uspension was then transferred onto six-well gelatin-coated
lates at a density of 105 cells per well. Cells were
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Minocycline: A Novel Cardioprotective Agent March 3, 2004:865–74ubsequently washed in 1  phosphate buffered saline, and
he medium was replaced by one containing reduced FCS at
% (v/v), for an additional 24 h before experimentation.
ithin three days, a confluent monolayer of spontaneously
eating myocytes was formed.
Primary adult rat cardiomyocytes were prepared from
ix-month-old female Sprague-Dawley rats, as previously
escribed (7,8). Rats were sacrificed by cervical dislocation,
earts removed immediately, and immersed in buffer A with
-U/ml heparin. The aorta was identified and mounted on
he cannula of a Langendorff perfusion apparatus. Hearts
ere retrogradely perfused at 9 ml/min with buffer A
ontaining: 750 m CaCI2 (for the first 2 min); 100 m
GTA (for the following 4 min); and both 0.8 mg/ml
ollagenase type II and 200 m CaCI2 (for other 15 min).
earts were then removed, sectioned, and placed in buffer A
ith 0.8 mg/ml collagenase, 10% BSA, and 200 m CaCI2
or 5 min. Cells were filtered through a 200 m nylon
auze, resuspended in DMEM (containing 80 m EGTA,
% penicillin/streptomycin, and 1% fetal bovine serum), and
ncubated at 37°C with 5% CO2 for 1 h on laminin-coated
lates (10 to 15 g/ml). After replacement of the media,
ells were returned to the incubator and treated as required.
ll of the reagents mentioned in the Methods section,
nless differently stated, were purchased from Sigma-
ldrich (United Kingdom).
reatment of isolated myocytes. Myocytes were exposed
o simulated ischemia by incubation (4 h) in an ischemic
hamber and subsequently returned to a normoxic environ-
ent for 16 h to simulate reperfusion. Minocycline (0.02
m) and tetracycline (0.04 m) were added separately to
ultured myocytes 0, 1, 2, 4, and 24 h before hypoxia or at
eoxygenation.
ell death assessment in isolated myocytes. Single-cell
uspensions were incubated with annexin V and propidium
odide (PI) staining and immediately analyzed by flow
ytometer as previously reported (9,10). Red fluorescent
uclei, due to PI uptake, were used as indicators of necrosis.
reen annexin V staining, secondary to external exposure of
hosphatidylserine on the plasma membrane, was employed
s an early apoptotic marker.
nimal model. Hearts from anesthetized male Sprague-
Abbreviations and Acronyms
CPK  creatine phosphokinase
FP  forward primer
iNOS  inducible form of nitric oxide synthase
I/R  ischemia/reperfusion
LV  left ventricle/ventricular
LVEDP  left ventricular end-diastolic pressure
LVSP  left ventricular systolic pressure
PI  propidium iodide
RP  reverse primer
RT-PCR  reverse transcription-polymerase chain
reactionawley rats were perfused by the non-recirculating Lange- sdorff technique as previously described (11). Briefly, rats
ere anesthetized by sodium pentobarbital (6 mg/kg1
dministered intraperitoneally) and sacrificed by decapita-
ion. The hearts were removed, immersed in an ice-cold
odified Krebs-Hensleit buffer solution, and subsequently
erfused by the non-recirculating Langendorff technique at
constant flow of 11 ml/min. The heart rate was continu-
usly maintained at 300 beats/min by electrical pacing, and
he left ventricular (LV) wall was kept at the steady
emperature of 37°C.
reatment protocols. Isolated hearts were randomly di-
ided into eight groups (A, B, B1, C, D, D1, E, and E1) of
t least six hearts each. Group A (control group) was
erobically perfused for 60 min. Groups B and B1 were
erobically perfused (60 min) with the addition to the
erfusate of minocycline (1 m) and tetracycline (2 m),
espectively. Group C, D, D1, E, and E1 were exposed to
0 min of regional ischemia and 2 h of reperfusion. Group
was given minocycline ex vivo, at the dose of 1 m, 1 h
efore ischemia and during reperfusion. In group E, mino-
ycline was administered in vivo, over a period of three days
45 mg/kg intraperitoneally twice daily for the first day;
2.5 mg/kg for the subsequent two days), before isolation of
he hearts and their exposure to I/R. Similarly, group D1
as pretreated with tetracycline (2 m) before ischemia
1 h) and in the course of reperfusion. Finally, in group E1,
/R was preceded by in vivo treatment with tetracycline,
ccording to the following scheme: 90 mg/kg intraperito-
eally twice a day for the first day and 45 mg/kg during the
wo successive days.
egional ischemia. The left coronary artery of isolated
earts was surgically occluded for 30 min and subsequently
eperfused for 60 min as previously described (11).
nfarct size measurement. Measurement of risk area and
nfarct size was performed by triphenyl-tetrazolium chloride
taining as previously described (12). Triphenyl-tetrazolium
hloride stains all living tissue brick red, leaving the in-
arcted area unstained (white). Left ventricular infarct zone
as determined by computerized planimetry and expressed
s the percentage of infarcted area within the myocardium at
isk. Color enhancement was used to accentuate the differ-
nces between areas.
V pressure. Left ventricular systolic pressure (LVSP) and
eft ventricular end-diastolic pressure (LVEDP) were re-
orded as previously described (13). Briefly, to obtain an
sovolumetrically beating preparation, a latex balloon filled
ith saline, connected by a catheter to a Statham transducer
P 23 XL), was inserted into the LV through an atriotomy
nd secured by a suture around the atrioventricular groove.
he balloon was inflated to provide an end-diastolic pres-
ure 1.0 mm Hg.
ssay of creatine phosphokinase (CPK) in the coronary
ffluent. Creatine phosphokinase activity was evaluated by
pectrophotometry, as previously reported (14).
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March 3, 2004:865–74 Minocycline: A Novel Cardioprotective Agentaspase activity assay. Cardiac activation of caspase-3, -7,
8, and -9 was evaluated in tissue extracts, as previously
escribed (15).
UNEL enhanced with additional staining. After termi-
al deoxynucleotidyl transferase mediated nick end labeling
Boehringer Mannheim, Lewes, Sussex, United Kingdom)
TUNEL) staining, a previously described multiple-step
mmunocytochemical procedure was used (16). Myocardial
ections were labeled with either anti-desmin (Insight Bio-
echnology, Wembley, Middlesex, United Kingdom) or
nti–von Willebrand (Boehringer Mannheim Biochemica,
ewes, Sussex, United Kingdom) factor antibodies, in order
o selectively identify myocytes and endothelial cells, respec-
ively. After incubation with specific secondary antibodies,
he slides were counterstained with PI and finally examined
y confocal fluorescent microscopy. Data are expressed as
he means of 12 to 15 high-power fields SD.
everse transcription-polymerase chain reaction (RT-
CR). The following specific primers were used to semi-
uantitate transcript levels: caspase-1, forward primer (FP),
-GACCTCAGAGAAATGAAGTTG-3, reverse
rimer (RP), 5-CACGGCATGCCTGAATAATG-3;
aspase-3, FP, 5-GGTATTGAGACAGACAGTGG-3,
P, 5-CATGGGATCTGTTTCTTTGC-3; caspase-7,
P, 5-GATAAAGGATCTGACAGCTC-3; RP, 5-
ATGGACACCATACATGGAATC-3; caspase-8, FP,
-GAGCTGACATCTTACTTCAC-3, RP, 5-
AAGATGGGCTGTGGCATC-3; caspase-9, FP, 5-
TACATCGAGACCTTGGATG-3  , RP, 5 -
ACAGGATTACACAACCTCATG-3; caspase-12,
P, 5-CAGAAGTACAGGATTCACTG-3, RP,
-CATTCCTCATCTGTATCAGC-3; DIABLO, FP,
-GCATGACACTGTGTGCGGTTC-3, RP, 5-
CAACTGGATGTGATTCCTG-3; XIAP, FP, 5-
TACCTCTGGAACAAGGTGG-3  , RP, 5 -
AAGCTGCTCAGGCTGAAC-3; and rat cyclophilin,
P, 5-CGAGCTGTTTGCAGACAAAG-3, RP,
-TTCTTGCTGGTCTTGCCATT-3.
estern blotting. Western blot analysis was performed
ollowing standard protocols. Anti-procaspase-1, -3, -7, -8, -9,
12, anti-actin, anti-XIAP, and anti-Smac/DIABLO antibod-
es were obtained from Santa Cruz Biotechnology, Inc.
itochondrial and cytoplasmic protein fractionation,
haracterization, and assessment. Mitochondrial and cy-
oplasmic fractions from cardiac ventricular tissue were
solated as previously described (17). Anti-cytochrome C
nd anti-HSP60 antibodies were purchased from Abcam
Cambridge-Science-Park, United Kingdom).
tatistics. Data are expressed as means  SD, and the
ignificance level overall was set at p  0.05. Experiments
ere repeated at least three times. Single-factor one way
nalysis of variance was performed for each group of
reatments. Differences between treatment groups were
valuated using Student t test, and the Bonferroni cor-
ection was applied for multiple comparisons. The result-
ng significance level was p  0.008 (0.05/6) for cell oeath comparisons, and p  0.0125 (0.05/4) for infarct
isk ratio, TUNEL, and active caspase-3%. Analysis of
ovariance, with time as covariate and post hoc contrast
esting, was used to evaluate the hemodynamic variables.
ESULTS
inocycline is cardioprotective even when given at
eoxygenation. To investigate whether minocycline plays a
ole in cardioprotection, we first assessed cell death in
rimary cultures of neonatal and adult cardiomyocytes
reated with minocycline. Minocycline significantly reduced
ecrotic and apoptotic cell death, both in neonatal and adult
yocytes, not only when given before hypoxia, but also,
ore importantly, when given at reoxygenation. In neonatal
yocytes, the cardioprotective effect peaked when minocy-
line was administered 2 h before hypoxia (Fig. 1A).
ecrotic cell death decreased from 35.2  2.8% to 24.5 
.7% (p  0.001) and apoptotic death from 28.3  2% to
8.1  1.7% (p  0.001). In adult myocytes, the greatest
ardioprotection was achieved when minocycline was given
h before hypoxia (Fig. 1B). The magnitude of necrosis
38.1  2.7%) and apoptosis (29.5  2.3%) in untreated
yocytes diminished to 22.7  1.9% and 20.4  1.6%,
espectively (p  0.001). Post-hypoxic treatment with
inocycline prevented to a lesser, though still statistically
ignificant, extent, the degree of total cell death both in
eonatal and adult myocytes (p  0.05) (Figs. 1A and 1B).
n contrast, no cardioprotection was observed after addition
igure 1. Quantification of necrosis and apoptosis by flow cytometry in
rimary cultures of neonatal (A) and adult (B) myocytes. Data are
xpressed as mean  SD. *p  0.05; **p  0.01; ***p  0.001 vs.
schemic/reperfused (I/R) control (Ctrl). Open bars  necrosis; solid bars
apoptosis. MNC  minocycline.f tetracycline at any time point (data not shown).
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Minocycline: A Novel Cardioprotective Agent March 3, 2004:865–74inocycline promotes post-ischemic recovery of cardiac
unction independently of any direct hemodynamic effects.
o further validate these in vitro findings, we investigated a
otential cardioprotective effect of minocycline in the iso-
ated rat heart. First, we assessed whether minocycline
roduced any hemodynamic changes in the isolated heart in
he absence of any ischemic insult. Addition to the perfusate
f minocycline (concentration range: 105 to 107 M) had
o effect on either LVSP (Fig. 2A) or LVEDP (Fig. 2B).
imilarly, ex vivo infusion of increasing doses of tetracycline
igure 2. Hemodynamic measurements in the non-ischemic isolated rat h
eft ventricular systolic pressure (LVSP) and left ventricular end-diastolic p
ean  SD. Mechanical function of the isolated rat heart during ischemi
TRL  control; Solid triangles  LVSP; open squares  LVEDP.ad no effect on both LVSP and LVEDP (data not shown). pWe then evaluated the hemodynamic effects induced by
inocycline in rat hearts exposed to 30 min of regional
schemia followed by 2 h of reperfusion. Minocycline was
ither infused ex vivo (dose: 1 m) 1 h before ischemia and
uring reperfusion, or administered in vivo, over a period of
hree days (45 mg/kg intraperitoneally twice a day for the
rst day; 22.5 mg/kg for the subsequent two days), before
solation of the hearts and their exposure to I/R. Consistent
ith previous reports using the same experimental model of
/R injury (13), ischemic/reperfused control hearts showed a
erfused with minocycline (MNC) (105 to 107 M) for 1 h. Changes in
re (LVEDP) are shown in A and B, respectively. Results are expressed as
rfusion (I/R), with and without pretreatment with minocycline (C to E).eart p
ressu
a/reperogressive rise in LVEDP and a rapid decline in LVSP,
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March 3, 2004:865–74 Minocycline: A Novel Cardioprotective Agenthich recovered poorly during reperfusion (Fig. 2C). The
re- and post-ischemic infusion of minocycline significantly
educed the progressive rise of LVEDP observed during
/R. This recovery in LVEDP started after 10 min of
schemia (29.3  3.2 mm Hg after 20 min ischemia; p 
.025 vs. I/R control) and progressively improved through-
ut reperfusion. Because no concurrent enhancement in
VEDP was observed, the post-ischemic recovery of func-
ion in the hearts infused pre- and post-ischemia with
inocycline was only modest, though statistically significant
p  0.025 vs. control) (Fig. 2D). In contrast, in vivo
reatment with minocycline, extending over three days,
nduced not only a greater and earlier recovery of LVEDP
uring I/R, but also a rapid recovery of LVSP, which
ecame significant after 5 min of reperfusion (72  5.2 mm
g; p  0.025 vs. I/R control), and which progressively
mproved with partial normalization (86.0  5.9 mm Hg; p
0.001 vs. I/R control) at the end of reperfusion (Fig. 2E).
ence, the in vivo pretreatment with minocycline consis-
ently prevented the functional impairment in cardiac func-
ion associated with I/R injury (p  0.001 vs. I/R control).
n contrast, both ex vivo and in vivo administration of
etracycline had no effect on the hemodynamics of the
solated rat heart (data not shown).
inocycline minimizes infarct size and cardiac release of
PK after I/R. To address whether this amelioration in
ardiac performance is due to enhanced cell survival, we
valuated the extent of myocardial infarction, cardiac release
f CPK, and apoptotic cell death in the isolated rat heart
retreated with minocycline and subsequently exposed to
egional ischemia. In control hearts exposed to I/R, the
ercentage of infarction within the risk zone was 35 1.9%
Fig. 3A). Following pre- and post-ischemic infusion of
inocycline, the cardiac release of CPK (905  44 mU/
in/GWW; p  0.05 vs. I/R control), though not the
ercentage of infarction (p  0.0125), was significantly
educed (Figs. 3A and 3B). Conversely, the in vivo admin-
stration of minocycline over a three-day period resulted in
marked limitation of infarct size (p  0.001 vs. I/R
ontrol) (Figs. 3A, 3C to 3F), which was also associated
ith a strong attenuation of CPK release in the coronary
ffluent (737  36 mU/min/GWW after 30 min reperfu-
ion; p  0.001 vs. I/R control) (Fig. 3B). In contrast, both
x vivo and in vivo treatment with tetracycline did not result
n any significant reduction in infarct size and CPK release
Figs. 3A and 3B).
inocycline prevents both endothelial and myocyte ap-
ptosis in the intact heart exposed to ischemia/reperfusion.
n agreement with our previous studies, TUNEL-positive
taining was detected only during reperfusion (11,13,15,16)
nd always colocalized with caspase-3-positive labeling
13,16). Additionally, the magnitude of apoptotic cell death
as much higher in endothelial cells than in cardiac myo-
ytes (15,16). The three-day in vivo treatment with mino-
ycline produced a highly significant reduction in these
poptotic markers in both cell types (p  0.001 vs. I/R fontrol) (Figs. 3G, 3H, and 4). Although less profound, the
essening in apoptosis remained significant when minocy-
line was given by infusion before and after ischemia
p  0.001 vs. I/R control). Reduction of TUNEL- and
aspase-3-positive staining was not observed after either ex
ivo nor in vivo treatment with tetracycline (Figs. 3G and
H). Hence, the modest, though significant, post-ischemic
ecovery of function observed after ex vivo infusion of
inocycline was associated with a significant decrease in
ardiac release of CPK and a non-significant limitation of
nfarct size. In contrast, after in vivo treatment with mino-
ycline, the post-ischemic recovery of cardiac function was
reatly enhanced and paralleled a marked reduction of both
nfarct size and myocardial release of CPK.
inocycline induces cardiac downregulation of both
nitiator and effector caspases. By RT-PCR and Western
lot analysis, ischemic/reperfused control hearts showed a
hreefold or more transcriptional and translational up-
egulation of caspase-1, -3, -7, -8, -9, and -12 (Figs. 5A and
B). In hearts given three-day treatment with minocycline
efore exposure to I/R, the messenger RNA and protein
nduction of all the above caspases was dramatically reduced.
imilarly, in control hearts unexposed to I/R receiving
inocycline intraperitoneally for three days, the basal mes-
enger RNA and protein expression level of caspases-1, -3,
7, -8, -9, and -12 was greatly downregulated compared
ith control hearts unexposed to I/R.
In agreement with these findings, in control hearts
xposed to I/R, the activity level of initiator (caspase-8 and
9) and effector caspases (caspase-3 and -7) was increased
ompared with control hearts. Hearts subjected to three-day
n vivo treatment with minocycline showed a greatly re-
uced level of functional activation of caspase-3, -7, -8, and
9 after I/R compared with ischemic/reperfused control
earts (p  0.001 vs. I/R control) (Fig. 5C). Therefore, in
ddition to the downregulation of effector caspase expres-
ion previously reported in the brain (3,4,6), this study
hows for the first time that minocycline downregulates not
nly the expression, but also the activity, of both initiator
nd effector caspases in a different target organ.
ffect of minocycline on XIAP and the mitochondrial
roteins, cytochrome c and Smac/DIABLO. One stim-
lus by which cells are induced to undergo apoptosis is
itochondrial damage with release of cytochrome c and
ctivation of caspase-9. The cytoplasmic relocation of cyto-
hrome c seen in ischemic control hearts was remarkably
educed in rat hearts exposed to I/R after in vivo treatment
ith minocycline, although the total mitochondrial levels of
ytochrome c were unaffected (Fig. 5D). Caspase activation
s also dependent on the ratio between the inhibitors of
poptosis and another mitochondrial protein, Smac/
IABLO. In untreated perfused hearts exposed to I/R,
xpression of XIAP was reduced, together with a marked
nduction of Smac/DIABLO at both transcript and protein
evels (Fig. 5D). In contrast, administration of minocycline
or three days before I/R induced enhanced expression of
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Minocycline: A Novel Cardioprotective Agent March 3, 2004:865–74igure 3. Infarct size, expressed as a percentage of myocardial risk zone (A), and post-ischemic release of creatine phosphokinase (CPK) (B) in
schemic/reperfused (I/R) control (Ctrl) hearts and hearts exposed to I/R, following ex vivo and in vivo treatment with either minocycline (Mnc) or
etracycline (Tcn). Data are expressed as mean  SD. ***p  0.001 versus non-ischemic control hearts. Infarcted areas, assessed by triphenyl-tetrazolium
hloride exclusion, in I/R control (C) and in vivo minocycline-treated (D) hearts. The corresponding color-enhanced images (white  infarcted area; green
area at risk; red  non-ischemic zone) are depicted in E (Ctrl hearts) and F (Mnc-treated hearts), respectively. Percentages of TUNEL (G) and cleaved
ctive caspase-3 (C3) (H) positive endothelial cells (EC) and cardiac myocytes (CM) in control hearts exposed or unexposed to I/R, and in I/R hearts
retreated ex vivo and in vivo with either Mnc or Tcn. Values are averages of three independent experiments SD. ***p  0.001 vs. ischemic Ctrl hearts.
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March 3, 2004:865–74 Minocycline: A Novel Cardioprotective AgentIAP with concurrent downregulation of Smac/DIABLO
xpression. Strong induction of XIAP, with reduced Smac/
IABLO expression, was also seen in the hearts of
inocycline-treated animals that were not subjected to I/R
Fig. 5D). Consistent with these findings, the levels of
mac/DIABLO in the mitochondria of hearts from
inocycline-treated rats was also reduced. Moreover, mi-
ocycline treatment reduced translocation of Smac/
IABLO from mitochondria into the cytosol, similar to its
ffects on cytochrome c translocation. Therefore, the pro-
ective effects of minocycline are mediated by a number of
rocesses. This antibiotic diminishes the level and activity of
aspases; it reduces mitochondrial leakage of cytochrome c
fter I/R, thereby reducing activation of the apical caspase,
aspase-9; and, finally, it increases the cytoplasmic ratio of
IAP to Smac/DIABLO, both by altering the expression of
hese proteins and by minimizing mitochondrial leakage of
mac/DIABLO.
ISCUSSION
ere, we show for the first time that minocycline induces
rotection against I/R injury in the heart and substantiates
igure 4. Myocardial sections from control and treated hearts stained by T
dentified by specific anti-desmin (C and F) and von Willebrand (D a
UNEL-positive cells (A and B). In ischemic/reperfused (I/R) control he
nd endothelial cells (E). In vivo treatment with minocycline (Mnc) signific
agnification: 400.ur findings by providing new insights into its mechanism ef action. Our study demonstrates that minocycline effec-
ively protects cardiac myocytes against I/R injury, inducing
marked reduction in both necrotic and apoptotic cell
eath. This cardioprotective effect has been validated at
hree levels: in vitro, using primary cultures of neonatal and
dult cardiomyocytes; ex vivo, infusing minocycline to the
solated rat heart; and in vivo, injecting the animals with
inocycline over a period of three days. Importantly,
eduction of infarct size and apoptotic cell death observed
fter in vivo treatment with minocycline was associated with
remarkable post-ischemic recovery of cardiac function.
owever, because our findings refer solely to the use of in
itro models of ischemia/reperfusion, data supporting sim-
lar effects of minocycline on chronic infarct size in the
lood-perfused heart subjected to regional ischemia are also
equired.
There are many determinants of cellular fate after stres-
ors such as I/R injury, including the balance between
ntrinsic death and survival factors within the apoptotic
rogram. Although we have identified some mechanisms of
inocycline-mediated cardioprotection, these are not nec-
ssarily the only, or even the most important, effects. For
L and propidium iodide. Myocytes and endothelial cells were selectively
) labeling, respectively. Non-ischemic control hearts exhibit no yellow
TUNEL-positivity was consistently observed both in cardiomyocytes (C)
reduced the magnitude of apoptosis in both cell types (F and H). OriginalUNE
nd G
arts,
antlyxample, modulation of the production of free radicals,
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undamental property of the drug, and this possibility is
urrently under investigation.
The cardioprotective properties of minocycline are not
hared by its ancestral antibiotic, tetracycline. The newer
etracyclines have a variety of substituted groups at various
ositions in the basic four-ring structure, which have the
ffect of broadening their antibiotic spectrum, at least
artially as a result of increasing their solubility in the lipid
embranes of bacteria. Minocycline, uniquely, has an
(CH3)2 group at position 7, and this may confer an ability
o protect cardiomyocytes and neurons and enhance its
igure 5. Reverse transcriptase-polymerase chain reaction (A) and Western
nd protein levels in cardiac tissues from hearts, exposed and unexposed, to i
orresponding densitometric analyses are shown at the bottom of each pa
tatistical analysis (*p 0.05; **p 0.01; ***p 0.001) was performed vers
inocycline [Mnc]) or exposed to I/R (ischemic hearts pretreated in vivonti-bacterial repertoire. tBesides the known downregulation of caspase-1 and -3,
e show that minocycline reduces the cardiac expression of
aspase-7, -8, -9, and -12 under basal conditions, and
revents the post-ischemic up-regulation of expression of all
hese caspases. Minocycline also interferes with upstream
nd downstream mechanisms leading to secondary caspase
ctivation and reactivation. After in vivo treatment with
inocycline, we report reduced mitochondrial leakage of
ytochrome c and Smac/DIABLO, together with an in-
reased ratio of XIAP to Smac/DIABLO. Therefore, the
ffects achieved with in vivo administration of minocycline
ffectively cooperate to restrict the level of caspase activity in
(B) of procaspase-1, -3, -7, -8, -9, -12, XIAP, and Smac/DIABLO RNA
ic/reperfusion (I/R), with and without in vivo treatment with minocycline.
alues are represented as relative fold change of the control value set to 1.
ntrol hearts (C) either unexposed (non-ischemic hearts treated in vivo with
minocycline). Continued on next page.blots
schem
nel. V
us co
withhe heart. Although rats given minocycline at doses as high
F
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March 3, 2004:865–74 Minocycline: A Novel Cardioprotective Agentigure 5 Continued. (C) Caspase-3, -7, -8, and -9 enzymatic activity in tissue extracts from non-ischemic and ischemic control hearts and hearts
retreated in vivo with minocycline and exposed to I/R. Data are expressed as mean  SD. ***p  0.001 vs. control hearts. (D) Expression levels of
ytochrome c and Smac/DIABLO proteins in mitochondrial and cytosolic fractions from control hearts exposed and unexposed to I/R, with and without
n vivo treatment with minocycline. HSP60 and actin were used as internal controls for the mitochondrial and cytosolic fractions, respectively. The
orrespondent densitometric evaluation is shown at the bottom of the panel. Values are represented as relative fold change of the control value set to 1.
tatistical analysis was performed as stated above. The reverse transcription-polymerase chain reaction and Western data are representative of five
xperiments performed in individual animals, and the in vivo treatment was performed as described in the Methods section and the legend to Figure 3.
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ivo doses of minocycline we used to achieve cardioprotec-
ion (90 mg/kg for the first day, and 45 mg/kg during the
ollowing two days) are undoubtedly high. These dosages,
hich in humans would correspond to approximately 1.5 g/
ay instead of the conventional 200 mg/day, may compro-
ise long-term utilization of the antibiotic as a cardiopro-
ective agent. Although this issue will have to be formally
nvestigated, previous reports have shown, however, that
aily tetracycline doses even higher than 2 g are still
elatively safe in healthy nonpregnant women (19). In
onclusion, we believe that minocycline could be valuable in
oth acute and possibly chronic clinical settings, where it
ay augment conventional cardioprotective agents in coun-
eracting the occurrence and progression of myocyte cell
oss. Additionally, provided that long-term treatment and
afety issues can be successfully resolved, minocycline, by
irtue of its oral bioavailability, may also be useful in
elaying the progression of chronic cardiovascular condi-
ions, such as heart failure and cardiomyopathies, where
rogressive cardiac cell loss is the ultimate mechanism
ccounting for cardiac dysfunction.
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